RxDoctor Payments Data

Amanda Cubit, NP

Family · Ada, OKNPI 1750882775

Payments from drug & device makers

$754in general payments, 2019–2025

Across 42 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$155
  • Novo Nordisk$95
  • AbbVie$94
  • Pfizer$80
  • Sumitomo Pharma America, Inc.$70
  • Lundbeck LLC$48
  • plus $212 from 9 others

What the payments were for

  • Food & beverage$754100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$754 in reported general payments places this provider in the 65th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$4,460
Medicare patients
114
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$121,044
OzempicSemaglutide23$55,058
FarxigaDapagliflozin Propanediol33$54,097
TrulicityDulaglutide37$47,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$47,819
EliquisApixaban16$23,965
WegovySemaglutide13$21,614
GemtesaVibegron18$19,756
RexultiBrexpiprazole13$19,235
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$17,853
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$6,068
Omeprazole90$4,914
AbrysvoRsv Vacc, Pref A And Pref B/Pf15$4,547
Atorvastatin Calcium168$3,208
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$47$168,946128 claims
Novo NordiskOzempic, Wegovy$95$76,67236 claims
AstraZenecaFarxiga, Breztri Aerosphere$155$71,95047 claims
GSKTrelegy Ellipta, Shingrix$14$50,99745 claims
PfizerEliquis, Abrysvo$80$28,51231 claims
Sumitomo Pharma America, Inc.Gemtesa$70$19,75618 claims
AbbVieSynthroid$94$65111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,026 family providers in Oklahoma.

Other family in Ada

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →